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RESULTS

OBJECTIVE
The aim of this study was to evaluate compliance to the newly implemented fixed dosing protocol
while assessing for the need for repeat doses of 4F-PCC and the need for further invasive
intervention to reverse the bleeding

BACKGROUND
Patients presenting with an acute life-threatening bleed while taking warfarin or direct oral
anticoagulants (DOAC) often require emergent reversal. In the setting of acute bleeding, while 4FPCC has been routinely used as a reversal agent, its optimal dosing regimen remains controversial.
Currently manufacturer dosing is pretreatment, INR restricted, and weight based as listed below:
Pre-treatment INR

2-4

4-6

Greater than 6

4F-PCC Dose

25 units/kg

35 units/kg

50 units/kg

Max dose

2500 units

3500 units

5000 units

Additionally, 4F-PCC only has a Food and Drug Administration (FDA) indication for warfarin reversal
despite its common use in reversal of DOAC-related bleeding. A fixed dose strategy can have many
advantages including shorter preparation time and thereby shorter time to administration, and
overall lower doses resulting in reduced cost. In addition, the operational advantage of using a fixed
dose is another contributor to the cost reduction of weight-based restriction doses.
In 2020, Parkview Health system in Fort Wayne, IN implemented a protocol utilizing a fixed-dose
weight-based 4F-PCC dosing schedule in patients with life threatening warfarin or DOAC-related
bleeding.
- Patient weight <50 kg = 4F-PCC 25 units/kg +/- 10%
- Patient weight 50 kg-100 kg = 4F-PCC 2000 units +/- 10% (1800-2200 units)
- Patient weight >100 kg = 4F-PCC 2500 units +/- 10% (2250-2750 units)
- Re-dose with 4F-PCC 500 units +/- 10% as needed for continued bleeding

METHODS

•
•
•
•

•

We conducted an institutional review board exempt retrospective drug use evaluation extracting
pertinent patient information from the electronic health record
Main variables of interest collected: age, weight, classification for 4F-PCC use or location of
bleed, type of anticoagulant prior to use, indication for anticoagulation, 4F-PCC dose information,
use of blood products/phytonadione, and need for further invasive intervention.
Any surgical procedure primarily intended for bleeding control within 48 hours post 4F-PCC
administration was classified as invasive intervention.
Further analysis compared actual dose administered with the package insert recommended dose
to evaluate the difference in cost between fixed dosing and traditional dosing.
Two models were used for cost-analysis due to the variability in dosing for non-warfarin related
bleeding.
• First model: Utilized 4F-PCC package insert dose recommendations for warfarin-related
bleeding reversal with INR-restricted weight-based dosing (25 units/kg if no INR available)
with maximum dose adjustment for patients weighing over 100 kg.
• For non-warfarin related bleeding reversal, 25 units/kg was used as standard
recommended dosing with no maximum dose adjustment.
• Second model: The 4F-PCC package insert was utilized restricted by pretreatment INR and
weight-based (25 units/kg if no INR available) with the same maximum dose adjustment.
• For non-warfarin related bleeding reversal, 50 units/kg was used as the standard dosing
with no maximum dose adjustment.
Average wholesale price (AWP) of $3.14/unit was used to estimate cost-savings between the
different models and dosing strategies.

Of the 59 patients with warfarin use prior to reversal, 51 also received phytonadione as
recommended with use of 4F-PCC. We saw phytonadione use with 4F-PCC in non-warfarin related
bleeds including 5 patients with DOAC use prior to reversal and in 5 patients with no anticoagulation
use.
A comparison in the number of 4F-PCC units (Table 4) administered to standard recommended
dosing showed considerable dose reductions in warfarin and non-warfarin reversal. Regardless of
which model, fixed dosing resulted in considerable cost reduction when compared to
standard dosing. Given the potential variability in cost reduction, the two models provide a range of
savings that can be expected.
Model 1
Model 2

# of administrations (n = 119)
74 (+/-12)
62 (52%)
104 (87%)
115 (97%)
89 (+/- 30)
30.2 (+/- 10.6)
41 (34.5%)
2.3
9 (8%)
9 (8%)
1 (1%)

Age (years), average (SD)
Sex (male) , n (%)
Race (white), n (%)
Not Hispanic or Latino, n (%)
Weight (kg), average (SD)
Body Mass Index, average (SD)
Received at least one unit of PRBC, n (%)
Average number of PRBC units received
Received at least one unit of platelets, n (%)
Received at least one unit of FFP, n (%)
Received at least one unit of cryoprecipitate, n (%)

Difference in units

Table 1: Sample population characteristics | PRBC: Packed red blood cell; FFP: Fresh frozen plasma

• Nine encounters were excluded due to massive blood transfusion protocol
• Of the 119 administrations collected and analyzed, there was a single incidence of 4F-PCC redosing
(post-operative surgical bleeding).
• The most common indication for any anticoagulant use was atrial fibrillation (76%) followed by venous
thromboembolism (21%).
• Seventy-six percent of administrations (91 out of 119) complied with the health system dosing protocol
based on accepted dosing range with the noted variability of available products.
• Overall, there was a lack of need for invasive intervention. Of the 119 administrations, 100 (84%) didn’t
require invasive intervention within 48 hours of 4F-PCC administration. Seven of those administrations
were in the pre-surgical setting of 4F-PCC use where this attribute is not applicable. (Tables 2 and 3).
TIME (HOURS) SINCE LAST ANTICOAGULATION DOSE

Unknown time since
last anticoagulation
dose (17%)

Apixaban
30%

Dabigatran
1%
Fondaparinux
1%

Rivaroxaban
13%

>30 hours since last
anticoagulation dose
(14%)

•

•

•
•

Warfarin
49%

DISTRIBUTION OF 4F-PCC CATEGORY FOR USE
Unknown

•

2

Supratherapeutic INR

•

11

Pre-surgical

14

Other Bleed

•
18

ICH

30

GI Bleed

44
0

5

10

15

20

25

30

35

40

45

50

Cost reduction ($)

DISCUSSION & CONCLUSIONS

None
6%

18-30 hours since last
anticoagulation dose
(53%)

Difference in units

Other includes encounters where no anticoagulation or fondaparinux is used; DOACs include rivaroxaban, apixaban, and
dabigatran.

DISTRIBUTION OF ANTICOAGULATION USE

<18 hours since last
anticoagulation
dose
(16%)

Cost reduction ($)

All anticoagulants
-52,295
$164,206.30
-160,460
$503,844.40
Warfarin only
-25,926
$81,407.64
-25,926
$81,407.64
DOACs only
-26,308
$82,607.12
-119,674
$375,776.36
Other
-61
$191.54
-14,860
$46,660.40
Table 4: Difference in number of units and cost ($) between using the health system protocol and
standard recommended dosing (stratified by the anticoagulant type needing reversal)

•

Inclusion Criteria
• 18 years or older
• Received at least one dose of 4F-PCC within the Parkview Health system between November
1, 2020, to June 15, 2021.
Exclusion Criteria
• Eligible for and treated with massive transfusion protocol
•

RESULTS

During a seven-month period, 4F-PCC was administered adherent to hospital dosing protocol
with minimal need for redosing. Although the assessed dosing regimen is clear, it can be difficult
to accurately dose 4F-PCC when considering variability of the available products and the dosage
vials manufactured.
The most common reversal need for bleeding was in atrial fibrillation patients on warfarin
therapy. Least commonly, 4F-PCC was used in supratherapeutic INR and in dabigatran or
fondaparinux anticoagulant use reversal which are not indicated treatments.
Utilization of this dosing protocol for 4F-PCC is associated with considerable cost minimization.
Both models comparing the two dosing regimens showed dose reductions and therefore cost
reductions when using the fixed dose weight-restricted dosing schedule compared to
the standard dose recommendations.
The assessed dosing regimen was also associated with certain positive outcomes including
limited needs for redosing and minimal requirements of invasive intervention for bleeding control.
These results show that weight-restricted fixed dosing is an alternative for dosing 4F-PCC in
both warfarin and DOAC-related bleeding reversal.
• It can be advantageous especially in patients weighing over 100 kg particularly in cost
reduction.
• This dosing strategy is useful in dosing 4F-PCC for DOAC-related bleeding reversal as there
is no standard, package insert recommended dosing.
The clinical features in this subset were found to be consistent with values prior to
implementation of the fixed-dose protocol.
Overall hemostasis, a commonly evaluated outcome, was not evaluated in our present study
thereby presenting a possible limitation of measuring efficacy.
Further limitations include the off-indication use of 4F-PCC. Occasionally, 4F-PCC was used
when there was no bleed or for reversal in DOAC-related bleeds; which may impact costanalysis and stand-in outcomes.
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Number of Patient Administrations
Need for further invasive
intervention

GI Bleed
n=44

ICH
n=30

Other Bleed
n=18

Pre-surgical
n=14

Supratherapeutic INR
n=11

Unknown
n=2

Grand Total

Yes

6 (14%)

3 (10%)

3 (17%)

0

0

0

12 (10%)

No

38 (86%)

27 (90%)

15 (83%)

7 (50%)

11 (100%)

2 (100%)

100 (84%)

N/A

0

0

0

7 (50%)

0

0

7 (6%)

Table 2: Need for further invasive intervention encounters classified by each bleed type.
Need for further invasive
intervention

Warfarin
n=59

Rivaroxaban
n=15

Apixaban
n=36

Dabigatran
n=1

Fondaparinux
n=1

None
n=7

Yes

4 (7%)

3 (20%)

5 (14%)

0

0

0

No

53 (90%)

12 (80%)

26 (72%)

1 (100%)

1 (100%)

7 (100%)

N/A

2 (3%)

0

5 (14%)

0

0

0

Table 3: Need for further invasive intervention patient encounters classified by anticoagulation used.
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